Investors Research Corp trimmed its position in Sanofi (NASDAQ:SNY) by 1.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,915 shares of the company’s stock after selling 375 shares during the quarter. Investors Research Corp’s holdings in Sanofi were worth $1,381,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently added to or reduced their stakes in the company. Cardinal Capital Management Inc. acquired a new position in Sanofi during the 1st quarter valued at $25,000. Reby Advisors LLC bought a new stake in Sanofi in the 4th quarter valued at $35,000. Arkadios Wealth Advisors bought a new stake in Sanofi in the 4th quarter valued at $36,000. Charter Oak Capital Management LLC bought a new stake in Sanofi in the 4th quarter valued at $40,000. Finally, JJJ Advisors Inc. increased its holdings in Sanofi by 193.8% in the 4th quarter. JJJ Advisors Inc. now owns 852 shares of the company’s stock valued at $41,000 after buying an additional 562 shares during the period. Hedge funds and other institutional investors own 6.93% of the company’s stock.
Shares of SNY traded down $0.40 during mid-day trading on Tuesday, hitting $50.49. 6,564 shares of the company’s stock were exchanged, compared to its average volume of 2,294,616. The company has a market cap of $127.13 billion, a PE ratio of 21.74, a P/E/G ratio of 1.90 and a beta of 0.55. Sanofi has a 52 week low of $44.76 and a 52 week high of $55.00. The company has a 50-day simple moving average of $50.43 and a 200 day simple moving average of $48.86. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.85 and a quick ratio of 1.38.
The company also recently announced an annual dividend, which will be paid on Wednesday, May 26th. Investors of record on Tuesday, May 4th will be paid a $1.9061 dividend. The ex-dividend date is Monday, May 3rd. This is a boost from Sanofi’s previous annual dividend of $1.21. This represents a dividend yield of 3.2%. Sanofi’s dividend payout ratio (DPR) is currently 35.24%.
Several equities research analysts have recently weighed in on SNY shares. Barclays reaffirmed an “equal weight” rating on shares of Sanofi in a report on Thursday, April 29th. Morgan Stanley reaffirmed an “overweight” rating on shares of Sanofi in a report on Wednesday, February 10th. UBS Group reiterated a “buy” rating on shares of Sanofi in a research report on Tuesday, January 19th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Sanofi in a research report on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Sanofi presently has an average rating of “Hold” and a consensus price target of $53.00.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Featured Story: How can investors find ex-dividend dates?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.